Sanofi pays up to USD 1bn for new multiple myeloma therapy
Following a licensing agreement with Eureka Therapeutics, Sanofi has acquired another drug candidate for multiple myeloma to join its portfolio alongside Sarclisa.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Sanofi is paying an undisclosed amount to forge a new license agreement with Eureka Therapeutics. However, the value of the deal might reach USD 1bn in subsequent milestone payments, according to a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
